MUC16 and ovarian cancer: Detection of a panel of biomarkers (EGFR, CA125, EGFR2, folate receptor α, CD9, CD24, and EpCAM) in circulating exosomes not only identified ovarian cancer patients from control subjects but also distinguished between early- and advanced- stage ovarian cancer [174].